Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 34 · MACD above its signal · 2% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.9M | 0.00% | 1.00M | +188% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ANVS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 19, 2026 | Hoffman Michael BDirector | Purchase at price 1.75 - 1.90 per share. | 76.3K | $142.78K |
| Apr 1, 2026 | Hoffman Michael BDirector | Purchase at price 2.10 per share. | 713.8K | $1.50M |
| Dec 7, 2025 | Hoffman Michael BDirector | Purchase at price 4.24 - 4.34 per share. | 45K | $193.79K |
| Nov 23, 2025 | Hoffman Michael BDirector | Purchase at price 3.85 - 4.15 per share. | 39.2K | $159.89K |
| Nov 23, 2025 | Hoffman Michael BDirector | Purchase at price 3.85 - 4.15 per share. | 39.2K | $159.89K |
| Nov 20, 2025 | Hoffman Michael BDirector | Purchase at price 3.49 - 3.50 per share. | 20K | $69.90K |
| Nov 13, 2025 | Hoffman Michael BDirector | Purchase at price 2.11 per share. | 15K | $31.65K |
| Oct 27, 2025 | Maccecchini Maria-LuisaChief Executive Officer | Purchase at price 2.05 per share. | 97.6K | $200.00K |
| Oct 27, 2025 | Hoffman Michael BDirector | Purchase at price 2.05 per share. | 975.6K | $2.00M |
| Sep 9, 2025 | Bruck ClaudineDirector | Conversion of Exercise of derivative security at price 0.14 per share. | 7.1K | $1.00K |
| Aug 28, 2025 | Hoffman Michael BDirector | Stock Award(Grant) at price 2.28 - 2.30 per share. | 15K | $34.35K |
| Aug 18, 2025 | Hoffman Michael BDirector | Stock Award(Grant) at price 2.57 - 2.60 per share. | 18.6K | $48.28K |
| Jun 15, 2025 | Walsh AndrewOfficer | Stock Award(Grant) at price 2.90 per share. | 500 | $1.45K |
| Jun 12, 2025 | Hoffman Michael BDirector | Stock Award(Grant) at price 2.80 - 2.83 per share. | 25K | $70.00K |
| Jun 9, 2025 | Mccarthy Reid S.Director | Stock Award(Grant) at price 2.95 per share. | 2K | $5.90K |
| Jun 3, 2025 | Maccecchini Maria-LuisaChief Executive Officer | Stock Award(Grant) at price 3.37 per share. | 46K | $155.02K |
| May 28, 2025 | Hoffman Michael BDirector | Stock Award(Grant) at price 2.43 per share. | 5K | $12.15K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -22.0 | -0.7 | -16.8 | -11.7 | -2.5 | -3.1 | -5.9 | -1.7 | -26.2 | -16.5 | −69.4% | ||
| 2025 | -3.2 | -62.4 | -18.0 | -0.7 | 57.7 | -7.7 | 25.8 | -15.4 | -10.4 | 1.4 | 142.9 | -32.2 | −31.2% |
| 2024 | -40.9 | -23.3 | 40.5 | -53.2 | 17.6 | -12.1 | 61.6 | -9.1 | -4.7 | 15.1 | -27.7 | -25.0 | −73.1% |
| 2023 | 23.0 | 3.6 | -9.9 | -5.5 | -10.1 | 9.1 | -3.5 | -10.1 | -23.5 | -30.3 | 28.4 | 120.3 | +39.2% |
| 2022 | -13.7 | -6.4 | -6.0 | -29.3 | -2.8 | 23.5 | 1.4 | 0.9 | 18.1 | -8.4 | 7.1 | -0.1 | −23.6% |
| 2021 | 32.4 | 156.2 | 9.1 | -20.6 | 103.7 | 89.8 | -59.8 | 9.6 | -15.9 | -16.5 | -9.3 | -26.9 | +133.2% |
| 2020 | -25.6 | -38.1 | 28.3 | 15.3 | -2.0 | 33.3 | -18.1 | 1.3 | -5.2 | 19.5 | 38.3 | +15.6% |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Buy / hold / sell counts